Journal of Korean Society for Clinical Pharmacology and Therapeutics (임상약리학회지)
- Volume 14 Issue 1
- /
- Pages.58-64
- /
- 2006
- /
- 1225-5467(pISSN)
Multicenter Study for the Efficacy of Godex in Patients with Chronic Liver Disease and Liver Cirrhosis
만성간염 및 간경변증 환자에서 고덱스(Godex)의 효과에 대한 다기관 공동연구
- Yoo, Tae-Woo (Sungkyunkwan University School of Medicine) ;
- Kweon, Young-Oh (Kyungpook National University College of Medicine) ;
- Lee, Joung-Il (Kyung Hee University College of Medicine) ;
- Han, Byung-Hun (Kosin University Gospel Hospital) ;
- Cho, Mong (Pusan National University College of Medicine) ;
-
Hwang, Seong-Gyu
(Pochon CHA University College of Medicine)
;
- Kim, Yun-Soo (Soon Chun Hyang University College of Medicine) ;
- Chon, Chae-Yoon (Yonsei University College of Medicine) ;
- Lee, Seung-Ok (Chonbuk National University College of Medicine) ;
- Song, Byung-Cheol (Cheju National University College of Medicine) ;
- Lee, Byung-Seok (Chungnam National University College of Medicine) ;
- Sohn, Ju-Hyun (Hanyang University College of Medicine) ;
- Kim, Byung-Ik (Sungkyunkwan University School of Medicine)
- 유태우 (강북삼성병원) ;
- 권영오 (경북대병원) ;
- 이정일 (경희의료원) ;
- 한병훈 (고신의료원) ;
- 조몽 (부산대병원) ;
-
황성규
(분당차병원)
;
- 김연수 (순천향병원) ;
- 전재윤 (신촌세브란스병원) ;
- 이승옥 (전북대병원) ;
- 송병철 (제주대병원) ;
- 이병석 (충남대병원) ;
- 손주현 (한양대구리병원) ;
- 김병익 (강북삼성병원)
- Published : 2006.06.30
Abstract
Godex is a mixture of hepadif and biphenyl dimethyl dicarboxylate (DDB), which has hepatoprotective activity. This study evaluated the effect of Godex on biochemical items associated with liver function and hepatitis B virus DNA level to patients with chronic hepatitis, fatty liver and liver cirrhosis. A total of 242 patients with chronic hepatitis, fatty liver and liver cirrhosis who visited to 12 medical centers from Sep. 2002 to Feb. 2005 and have no other medicines except it were enrolled in this study. We retrospectively evaluated the changes of biochemical items such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, albumin, prothrombin time, platelet count and hepatitis B virus DNA level before and at 1, 3, 6, 9 and 12 months after the Codex treatment. In patients with chronic hepatitis, ALT and total bilirubin have shown statistically significant changes (p<0.05). In patients with fatty liver and liver cirrhosis, the ALT level alone was significantly changed (p<0.05). Otherwise, hepatitis B virus DNA level was not changed Even if some biochemical items were improved in patients with chronic hepatitis, fatty liver and liver cirrhosis after Godex treatment it did not affect the change of hepatitis B virus DNA level.